Evommune (EVMN) Income Statement (2024 - 2026)
Income Statement report data from Sep 30, 2024 to Mar 31, 2026 for Evommune (EVMN).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Sep 30, 2025 | Mar 31, 2025 | Sep 30, 2024 | |
|---|---|---|---|---|
Revenue and COGS | ||||
Total Revenue | - | 10M (+233.33%) | 3.00M | - |
Operating Expenses | ||||
Research And Development | 17M (-11.81%) | 20M (+36.77%) | 14M (+8.05%) | 13M |
Selling General And Administrative | 6.64M (+79.95%) | 3.69M (+0.54%) | 3.67M (+13.62%) | 3.23M |
Operating Expenses | 24M (+2.66%) | 23M (+29.40%) | 18M (+9.14%) | 17M |
Depreciation And Amortization | 100K | - | 200K | - |
Operating Income | ||||
Operating Income | -23.95M (+79.67%) | -13.33M (-11.31%) | -15.03M (-9.02%) | -16.52M |
Ebit | -23.95M (+79.67%) | -13.33M (-11.31%) | -15.03M (-9.02%) | -16.52M |
EBITDA | -23.85M (+91.26%) | -12.47M (-15.91%) | -14.83M (-6.85%) | -15.92M |
Other Income / Expenses | ||||
Interest Income | 2.28M (+165.12%) | 860K (+40.98%) | 610K (-1.61%) | 620K |
Net Interest Income | 2.28M (+165.12%) | 860K (+40.98%) | 610K (-1.61%) | 620K |
Other Non Operating Income | 2.28M (+168.24%) | 850K (+77.08%) | 480K (-20.00%) | 600K |
Net Income | ||||
Net Income From Continuing Operations | -21.67M (+73.78%) | -12.47M (-14.35%) | -14.56M (-8.54%) | -15.92M |
Net Income | -21.67M (+73.78%) | -12.47M (-14.35%) | -14.56M (-8.54%) | -15.92M |